泰达生物(08189)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

08189 泰达生物

休市中 09-11 15:42:20

0.255

-0.005

-1.92%

最高0.280	最低0.250	成交量20.00万
今开0.270	昨收0.260	日振幅11.54%
总市值5.44亿	流通市值3.66亿	总股本21.34亿
成交额5.14万	换手率0.01%	流通股本14.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"08189","market":"HK","secType":"STK","nameCN":"泰达生物","latestPrice":0.255,"timestamp":1789112540244,"preClose":0.26,"halted":0,"volume":200000,"delay":0,"changeRate":-0.019230769230769246,"floatShares":1436400000,"shares":2134000000,"eps":-0.043671,"marketStatus":"休市中","change":-0.005,"latestTime":"09-11 15:42:20","open":0.27,"high":0.28,"low":0.25,"amount":51400,"amplitude":0.115385,"askPrice":0.255,"askSize":160000,"bidPrice":0.249,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":-0.04,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":7,"adr":0,"listingDate":1024329600000,"exchange":"SEHK","adjPreClose":0.26,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.05067139599529078,"lotSize":5000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/08189","defaultTab":"news","newsList":[{"id":"1187308349","title":"泰达生物(08189)子公司医数精诚与中通建设计院签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1187308349","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187308349?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:41","pubTimestamp":1788864070,"startTime":"0","endTime":"0","summary":"2026年9月8日，泰达生物发布自愿公告称，其控股子公司深圳医数精诚科技有限公司已与中国通信建设集团有限公司旗下全资咨询设计企业中国通信建设集团设计院有限公司签署战略合作协议。医数精诚负责数据清洗、数据智能分析及定制化模型训练等全流程数据服务；中通建设计院将利用其资质、技术力量及项目经验保障项目顺利实施。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185906126","title":"泰达生物（08189）与湖南星辰通用机器人签署战略合作框架协议 布局医疗健康具身智能","url":"https://stock-news.laohu8.com/highlight/detail?id=1185906126","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185906126?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:40","pubTimestamp":1788864055,"startTime":"0","endTime":"0","summary":"2026年9月8日，泰达生物发布自愿公告称，公司已与湖南星辰通用机器人有限公司签署战略合作框架协议，双方将围绕“医疗健康大模型+具身智能”展开深度合作。\\n\\n泰达生物表示，合作将把其在医疗健康大模型与垂类智能体方面的技术，与星辰通用在具身智能全栈技术及机器人硬件领域的优势深度结合，构建覆盖“数据治理—模型研发—终端适配—场景应用—持续迭代—产业推广”的闭环体系。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324454","title":"泰达生物(08189)与星辰通用签署战略合作框架协议 共同推动医疗健康具身智能技术体系、产品体系和解决方案的形成与产业化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324454","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665324454?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:40","pubTimestamp":1788864000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物 公布，公司与湖南星辰通用机器人有限公司已签署战略合作框架协议。双方将本着平等自愿、优势互补、场景牵引、联合创新、资源共享、长期合作的原则，围绕医疗健康大模型与具身智能技术的深度融合，共同推动医疗健康具身智能技术体系、产品体系和解决方案的形成与产业化落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","BK1113","XBI","BK4588","LABU","XLV","159760","BK4585","08189","BK4550","WDRN","IXJ","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196547995","title":"泰达生物(08189)：多方携手共建具身智能场景开放中心等项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1196547995","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196547995?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:38","pubTimestamp":1788863892,"startTime":"0","endTime":"0","summary":"泰达生物(08189)宣布，将与相关参与方共同推进具身智能场景开放中心及其他项目的落地。\n这项合作计划旨在整合各方资源，加速具身智能技术在实际场景中的应用与推广。\n通过设立开放中心，各方期望为行业搭建更高效的协同平台，助力智能技术从研发迈向产业化。\n此外，合作内容还涵盖了一系列相关配套举措，为未来多场景落地奠定基础。\n泰达生物表示，此举是其拓展新兴技术领域、探索多元化发展路径的积极一步。\n后续进展值得市场关注，具体合作细节及项目推进计划预计将在适当时间对外公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189","BK1113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142354803","title":"泰达生物携手深圳一术精诚科技，多方达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1142354803","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142354803?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:36","pubTimestamp":1788863800,"startTime":"0","endTime":"0","summary":"泰达生物（TEDA Biomedical）与深圳一术精诚科技等多方正式签署合作协议，开启协同发展新篇章。此次合作涉及多方主体，旨在整合各自资源与技术优势，推动相关领域的深度布局。协议的达成标志着各方在产业链协作上迈出关键一步，未来有望通过优势互补实现共赢局面。尽管具体合作细节尚未完全披露，但这一举措已被市场视为泰达生物拓展业务边界、深化行业渗透的重要信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1113","08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132496","title":"泰达生物(08189.HK)控股子公司医数精诚与中通建设计院签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132496","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665132496?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:36","pubTimestamp":1788863796,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1113","08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156449173","title":"泰达生物战略合作：聚焦公共数据运营与行业大模型","url":"https://stock-news.laohu8.com/highlight/detail?id=1156449173","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156449173?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:35","pubTimestamp":1788863714,"startTime":"0","endTime":"0","summary":"泰达生物近日宣布，公司将展开一项新的战略合作，核心方向锁定在公共数据运营及行业大模型领域。通过整合多方资源与技术优势，泰达生物力图在数据驱动的产业升级中抢占先机。从短期的业务联动到长期的生态构建，泰达生物的战略选择显然经过深思熟虑。未来，随着合作的逐步落地，泰达生物在公共数据领域的参与深度，以及其大模型技术在行业中的应用成效，将成为观察其转型成色的关键窗口。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1113","08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124886608","title":"泰达生物（08189）拟修订章程 授权董事会三年内可发行不超已发行股份50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124886608","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124886608?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:51","pubTimestamp":1788774695,"startTime":"0","endTime":"0","summary":"2026年9月7日，天津泰达生物医学工程股份有限公司发布公告称，董事会建议修订公司章程，以符合2023年2月17日中国证监会发布的《境内企业境外发行证券和上市管理试行办法》及2023年12月29日修订通过、将于2024年7月1日起施行的《中华人民共和国公司法》相关规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153530617","title":"泰达生物更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1153530617","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153530617?lang=zh_cn&edition=full","pubTime":"2026-09-02 12:25","pubTimestamp":1788323142,"startTime":"0","endTime":"0","summary":"2026年9月2日，天津泰达生物医学工程股份有限公司（以下简称“泰达生物”，股票代码：08189）发布截至2026年8月31日的股份变动月报表。公告显示，该公司在本月未进行新增发行、购回或注销等活动，股本结构保持不变。\n根据公告，普通股方面，截至8月底，泰达生物H股数量为1,436,400,000股，内资股数量为697,500,000股，注册股本合计213,390,000元人民币，与上月底相比无变化。公司在报告期内未发生可换股债券、股票期权或其他股权激励计划的授予及行权等变动活动。\n公告同时显示，公司已确认满足香港联交所相关上市规则及法律法规的要求。关于本次月报表，由董事孙莉签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102803660","title":"泰达生物2026年上半年营收2.96亿元，归母净利润1,020.83万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102803660","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102803660?lang=zh_cn&edition=full","pubTime":"2026-08-31 22:02","pubTimestamp":1788184925,"startTime":"0","endTime":"0","summary":"泰达生物公布的2026年上半年财报显示，截至2026年6月30日，公司实现营收2.96亿元，同比增长30.75%。同期归母净利润1,020.83万元，去年同期则为-642.64万元；报告期内综合毛利率为11.27%，去年同期为6.10%。经营活动现金流较去年同期明显好转，上半年经营活动所用现金净额为3,749.56万元，去年同期则约为-9,839.76万元。财报显示，本期销售及分销费用为320.45万元，同比减少19.09%；研发及行政开支合计1,317.72万元，同比下降20.39%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"泰达生物2026年上半年营收2.96亿元，归母净利润1,020.83万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660451410","title":"泰达生物(08189)发盈喜 预期中期股东应占净利润约700万元至1000万元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2660451410","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660451410?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:52","pubTimestamp":1787028721,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物(08189)发布公告，截至2026年6月30日止6个月集团预期取得：收入约人民币2.9亿元至人民币3亿元，较截至2025年6月30日止6个月(去年同期)的收入约人民币2.26亿元，增加约28%至33%;及公司拥有人应占净利润约人民币700万元至人民币1000万元，较去年同期公司拥有人应占亏损约人民币600万元，增加约209%至256%, 实现扭亏为盈。报告期内收入及公司拥有人应占净利润增长主要来自于AI生命健康业务的快速扩展。报告期内AI生命健康业务取得收入约人民币1亿元至人民币1.1亿元，公司拥有人应占净利润约人民币1000万元到1200万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143888517","title":"泰达生物（08189）发盈喜：2026年上半年预盈最高1,000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143888517","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143888517?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:31","pubTimestamp":1787027479,"startTime":"0","endTime":"0","summary":"2026年8月18日，泰达生物公布盈利预告，预计截至2026年6月30日止六个月实现收入约2.9亿元至3亿元，较去年同期的2.26亿元增长约28%至33%。同期，公司预计录得归属于本公司股东的净利润约700万元至1,000万元，而去年同期为亏损约600万元，增幅约209%至256%，实现扭亏为盈。公司表示，上述数据基于未经审计的综合管理账目及董事会现有资料作出的初步评估，最终结果可能有所调整。泰达生物计划于2026年8月31日发布正式中期业绩。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192730897","title":"泰达生物预计2026年上半年净利润达700万至1000万元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1192730897","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192730897?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:27","pubTimestamp":1787027229,"startTime":"0","endTime":"0","summary":"泰达生物（Tianjin TEDA Biomedical Engineering Co）于今日发布公告，预期截至2026年6月30日止六个月将录得净利润介于700万元至1000万元人民币之间。这一业绩预告揭示了公司在近期经营活动中展现出的积极态势，尽管市场环境仍充满变数，但管理层对未来盈利能力抱持审慎乐观态度。值得注意的是，该预期数字反映了公司在成本控制与业务拓展方面所做出的持续努力，同时也暗示了行业复苏迹象初现端倪。不过，最终财务数据仍需以正式披露的中期报告为准，投资者应保持理性判断，密切关注后续公告详情。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1113","08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189784429","title":"泰达生物预期2026年上半年营收达2.9亿至3亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1189784429","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189784429?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:27","pubTimestamp":1787027228,"startTime":"0","endTime":"0","summary":"泰达生物（TEDA BIOMEDICAL）发布公告，预计截至2026年6月30日止六个月的营业收入将在2.9亿元人民币至3亿元人民币之间。这一预期反映了公司在生物医学工程领域持续拓展的积极态势，尽管市场环境复杂多变，公司仍展现出稳健的经营韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1113","08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107915885","title":"泰达生物（08189）拟于8月31日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1107915885","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107915885?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:42","pubTimestamp":1786696960,"startTime":"0","endTime":"0","summary":"泰达生物8月14日公告，公司董事会将于2026年8月31日10时在中国天津市天津经济技术开发区第四大街80号天大科技园A2座第9层召开董事会会议。\\n\\n根据GEM上市规则，本公告自刊发日期起至少连续七日于GEM网站及公司官网公开披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153845367","title":"泰达生物2026年7月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1153845367","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153845367?lang=zh_cn&edition=full","pubTime":"2026-08-03 11:46","pubTimestamp":1785728784,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司于2026年8月3日发布截至2026年7月31日的证券变动月报表。公告显示，公司本期没有新增股份发行、股份购回或注销等变动行为。公司披露，截至2026年7月31日，普通股H股注册股本维持1,436,400,000股，每股面值人民币0.1元，注册股本为人民币143,640,000元；内资股注册股本维持697,500,000股，每股面值人民币0.1元，注册股本为人民币69,750,000元。公告还显示，公司目前符合香港联交所对于股本及公众持股量的相关要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137702370","title":"泰达生物6月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1137702370","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137702370?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:28","pubTimestamp":1783074520,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司于2026年7月3日发布了截至2026年6月30日的月度股份变动报告，披露了公司在报告期内的股本结构与股份变动情况。报告显示，截至2026年6月30日，公司法定注册股本为人民币213,390,000元，股本结构维持不变，其中包括1,436,400,000股H股，以及697,500,000股内资股。本月内，公司已发行股份与库藏股份总数均未发生变化：H股、内资股数目分别保持1,436,400,000股及697,500,000股，未发生股票发行、购回、注销或库藏股变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184275716","title":"泰达生物更新2026年5月股份变动月报表 股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1184275716","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184275716?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:42","pubTimestamp":1780479775,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司于2026年06月03日发布2026年5月的股份变动月报表，覆盖2026年5月1日至5月31日期间公司股份状况。月报显示，泰达生物在本报告期内未进行任何新增股份发行或股本减少，也无股份回购、注销或库藏股操作。泰达生物在公告中确认公司已充分满足香港联交所的最低公众持股量要求，并表示上述事项均已履行相关法律法规以及香港联交所《上市规则》的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172418586","title":"泰达生物更新4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1172418586","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172418586?lang=zh_cn&edition=full","pubTime":"2026-05-04 10:02","pubTimestamp":1777860125,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司于2026年5月4日发布截至2026年4月30日的股份变动月报表。报告显示，公司当月未进行新增股份发行、购回或注销，整体股本结构保持稳定。根据公告，泰达生物截至2026年4月30日的注册股本总额为人民币213,390,000元，较上月无变化。报告期内，泰达生物未发生任何与股份期权计划或股权激励相关的股份授予、行使及失效事宜，也未进行任何形式的股份回购或注销操作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165977439","title":"泰达生物（08189）2025年营收上升35.68%，多元化业务并行下亏损扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1165977439","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165977439?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:21","pubTimestamp":1777551696,"startTime":"0","endTime":"0","summary":"天津泰达生物医学工程股份有限公司公布截至2025年12月31日止年度主要经营和财务情况，显示整体收入显著增长，但亏损幅度有所扩大。公司业务主要聚焦肥料产品和AI生命健康两大板块，持续推进产业链整合及跨领域协同。每股亏损由2024年度的人民币1.46分上升至4.37分。资产负债方面，截至2025年12月31日，资产总额约人民币2.65亿元，负债总额约人民币2.62亿元，股东应占权益约人民币1,222.4万元，较上年同期有所下滑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"泰达生物（08189）2025年营收上升35.68%，多元化业务并行下亏损扩大","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08189"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioteda.com","stockEarnings":[{"period":"1week","weight":0.0282},{"period":"1month","weight":0.7},{"period":"3month","weight":0.5269},{"period":"6month","weight":-0.15},{"period":"1year","weight":-0.4333},{"period":"ytd","weight":-0.1639}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"天津泰达生物医学工程股份有限公司是一家主要从事生物复合肥料产品的制造及销售的中国公司。该公司主要通过两个分部运营其业务。肥料产品分部从事制造及销售生物复合肥料产品（包括活性肥、不同配方的氮、磷及钾复合肥）、提供仓储服务以及肥料产品的加工及许可。养老及保健服务分部从事提供综合养老及保健服务，包括租赁老年人设备。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.541667,"avgChangeRate":0.014438},{"month":2,"riseRate":0.541667,"avgChangeRate":-0.007724},{"month":3,"riseRate":0.458333,"avgChangeRate":0.035341},{"month":4,"riseRate":0.208333,"avgChangeRate":0.000187},{"month":5,"riseRate":0.5,"avgChangeRate":0.09602},{"month":6,"riseRate":0.375,"avgChangeRate":-0.018794},{"month":7,"riseRate":0.4,"avgChangeRate":-0.025235},{"month":8,"riseRate":0.64,"avgChangeRate":0.188754},{"month":9,"riseRate":0.36,"avgChangeRate":-0.002223},{"month":10,"riseRate":0.208333,"avgChangeRate":-0.065134},{"month":11,"riseRate":0.291667,"avgChangeRate":0.035483},{"month":12,"riseRate":0.25,"avgChangeRate":0.00692}],"exchange":"SEHK","name":"泰达生物","nameEN":"TEDA BIOMEDICAL"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰达生物(08189)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰达生物(08189)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰达生物,08189,泰达生物股票,泰达生物股票老虎,泰达生物股票老虎国际,泰达生物行情,泰达生物股票行情,泰达生物股价,泰达生物股市,泰达生物股票价格,泰达生物股票交易,泰达生物股票购买,泰达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰达生物(08189)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰达生物(08189)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}